Somerville K W, Kitchingman G A, Langman M J
Eur J Clin Pharmacol. 1986;30(3):279-81. doi: 10.1007/BF00541528.
Famotidine, a new H2-receptor antagonist was tested for drug interactions using 14C-aminopyrine and antipyrine. Elimination of these model drugs was studied before and during 8 days of famotidine dosing in 8 healthy volunteers. Famotidine 40 mg b.d. did not inhibit aminopyrine 14CO2 half-life or antipyrine clearance although an unexpected mild enzyme inducing effect could not be excluded. It is unlikely that famotidine will inhibit hepatic drug metabolism during routine clinical use as the daily dose is expected to be 40 mg/day but interactions should be looked for if more prolonged or larger doses are used.
法莫替丁是一种新型H2受体拮抗剂，使用14C-氨基比林和安替比林对其进行了药物相互作用测试。在8名健康志愿者中，研究了在法莫替丁给药8天之前和期间这些模型药物的消除情况。法莫替丁40毫克，每日两次，并未抑制氨基比林14CO2半衰期或安替比林清除率，尽管不能排除意外的轻度酶诱导作用。在常规临床使用中，法莫替丁不太可能抑制肝脏药物代谢，因为预期日剂量为40毫克/天，但如果使用更长时间或更大剂量，则应寻找相互作用。
